Caplin Point Laboratories Limited — Nystatin Exporter Profile
Indian Pharmaceutical Exporter · #10 for Nystatin · $976.5K export value · DGFT Verified
Caplin Point Laboratories Limited is the #10 Indian exporter of Nystatin with $976.5K in export value and 66 verified shipments. Caplin Point Laboratories Limited holds a 1.9% market share in Nystatin exports across 5 countries. The company exports 55 pharmaceutical products worth $174.5M across 20 therapeutic categories.
Caplin Point Laboratories Limited — Nystatin Export Profile: Buyers & Destinations
Where Does Caplin Point Laboratories Limited Export Nystatin?
| Country | Value | Shipments | Share |
|---|---|---|---|
| DOMINICAN REPUBLIC | $257.8K | 10 | 28.1% |
| DOMINICAN REPULIC | $249.4K | 17 | 27.1% |
| GAUTEMALA | $240.9K | 22 | 26.2% |
| GUATEMALA | $98.9K | 9 | 10.8% |
| EL SALVADOR | $39.2K | 3 | 4.3% |
| ECUADOR | $24.2K | 3 | 2.6% |
| NICARAGUA | $8.6K | 2 | 0.9% |
Caplin Point Laboratories Limited exports Nystatin to 7 countries. The largest destination is DOMINICAN REPUBLIC accounting for 28.1% of Caplin Point Laboratories Limited's Nystatin shipments, followed by DOMINICAN REPULIC (27.1%) and GAUTEMALA (26.2%). These destinations reflect Caplin Point Laboratories Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Nystatin from Caplin Point Laboratories Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| SALDENT INTERNACIONAL S.R.L., | DOMINICAN REPULIC | $296.4K | 21 |
| NUEVOS ETICOS NEOETHICALS, S.A. | GAUTEMALA | $219.7K | 20 |
| SALDENT INTERNACIONAL SRLCARRETERA SANCHEZ KM | DOMINICAN REPUBLIC | $172.1K | 5 |
| NUEVOS ETICOS NEOETHICALS S.A. | GAUTEMALA | $66.8K | 6 |
| NUEVOS ETICOS NEOETHICALS S A | GAUTEMALA | $53.4K | 5 |
| SALDENT INTERNACIONAL S R L | DOMINICAN REPUBLIC | $38.7K | 1 |
| DROGUERIA SAIMED S.A. DE C.V., | EL SALVADOR | $21.1K | 2 |
| DROGUERIA SAIMED S.A. DE C.V. | EL SALVADOR | $18.1K | 1 |
| NEOETHICALS CIA LIMITEDA | ECUADOR | $14.3K | 1 |
| NEOETHICALS CIA LTDA | ECUADOR | $9.9K | 2 |
Caplin Point Laboratories Limited supplies Nystatin to 12 buyers globally. The largest buyer is SALDENT INTERNACIONAL S.R.L., (DOMINICAN REPULIC), followed by NUEVOS ETICOS NEOETHICALS, S.A. (GAUTEMALA) and SALDENT INTERNACIONAL SRLCARRETERA SANCHEZ KM (DOMINICAN REPUBLIC). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Nystatin Export Value and How Much Does Caplin Point Laboratories Limited Contribute?
India exported $26.6M worth of Nystatin through 2,442 shipments from 223 suppliers to 96 countries, serving 458 buyers globally. Caplin Point Laboratories Limited contributes $976.5K to this total, accounting for 1.9% of India's Nystatin exports. Caplin Point Laboratories Limited ships Nystatin to 7 countries through 12 buyers.
What Is the Average Shipment Value for Caplin Point Laboratories Limited's Nystatin Exports?
Caplin Point Laboratories Limited's average Nystatin shipment value is $14.8K per consignment, based on 66 shipments totaling $976.5K. The largest destination is DOMINICAN REPUBLIC (28.1% of Caplin Point Laboratories Limited's Nystatin exports).
How Does Caplin Point Laboratories Limited Compare to Other Indian Nystatin Exporters?
Caplin Point Laboratories Limited ranks #10 among 223 Indian Nystatin exporters with a 1.9% market share. The top 3 exporters are ZYDUS LIFESCIENCES LIMITED ($6.4M), TORRENT PHARMACEUTICALS LTD ($4.2M), MEDLEY PHARMACEUTICALS LIMITED ($3.5M). Caplin Point Laboratories Limited processed 66 shipments to 5 destination countries.
What Nystatin Formulations Does Caplin Point Laboratories Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| METRONIDAZOLE + NYSTATIN VAGINAL OVULES | $152.7K | 6 |
| NYSTATIN ORAL SUSPENSION BP 1,00,000 IU/ | $94.3K | 8 |
| METRONIDAZOLE AND NYSTATIN VAGINAL OVULE | $72.1K | 9 |
| METRONIDAZOLE AND NYSTATIN VAGINAL OVULES (500MG+100,000 IU) METRONIDAZOL + NISTATINA OVULOS VAGINALES 500MG+100, 000 U. | $59.1K | 2 |
| METRONIDAZOLE + NYSTATIN VAGINAL OVULES500MG+100000 IU-METRONIDAZOL + NISTATINA OVULOS VAGINALES 500MG+100 000 U.I- | $50.0K | 1 |
| METRONIDAZOLE + NYSTATIN VAGINAL OVULES500MG+100000 IU METRONIDAZOL + NISTATINA OVULOS VAGINALES 500MG+100 000 U.I | $50.0K | 1 |
| METRONIDAZOLE AND NYSTATIN VAGINAL OVULES (500MG+100,000 IU) METRONIDAZOL + NISTATINA OVULOS VAGINALES 500MG+100, 000 U.NOS | $48.0K | 3 |
| METRONIDAZOLE + NYSTATIN VAGINAL OVULES500MG+100,000 IU METRONIDAZOL + NISTATINA OVULOS VAGINALES 500MG+100, 000 U.I | $38.4K | 1 |
| NYSTATIN ORAL SUSPENSION BP 1,00,000 IU/ML | $36.2K | 3 |
| NYSTATIN ORAL SUSPENSION BP 100000 IU/ML | $36.0K | 3 |
Caplin Point Laboratories Limited exports 32 distinct Nystatin formulations including tablets, capsules, syrups, and combination drugs. The top formulation is METRONIDAZOLE + NYSTATIN VAGINAL OVULES with 6 shipments worth $152.7K. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
How Does Caplin Point Laboratories Limited Compare to Nearest Nystatin Exporters?
Exporters ranked immediately above and below #10 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 7 | MACLEODS PHARMACEUTICALS LTD | $1.2M | 157 | 6 | $7.3K |
| 9 | ALEMBIC PHARMACEUTICALS LIMITED | $988.1K | 79 | 1 | $12.5K |
| 10 | CAPLIN POINT LABORATORIES LIMITED ★ | $976.5K | 66 | 5 | $14.8K |
| 11 | S KANT HEALTHCARE LIMITED | $964.7K | 77 | 16 | $12.5K |
| 6 | VIVIMED LIFE SCIENCES PRIVATE LIMITED | $950.0K | 19 | 1 | $50.0K |
Caplin Point Laboratories Limited ranks #10 among 223 Indian Nystatin exporters. Average shipment value of $14.8K compared to the market average of $119.3K. The closest competitors by value are MACLEODS PHARMACEUTICALS LTD and ALEMBIC PHARMACEUTICALS LIMITED.
Which Indian Ports Ship Nystatin Exports?
| Port | Shipments | % Share |
|---|---|---|
| NHAVA SHEVA SEA (INNSA1) | 485 | 19.9% |
| JNPT/ NHAVA SHEVA SEA | 277 | 11.3% |
| JNPT | 208 | 8.5% |
| MUNDRA SEA | 120 | 4.9% |
| DELHI AIR | 105 | 4.3% |
| MUNDRA SEA (INMUN1) | 97 | 4.0% |
| AHEMDABAD ICD | 91 | 3.7% |
| DELHI AIR CARGO ACC (INDEL4) | 81 | 3.3% |
What Other Antifungals Products Does Caplin Point Laboratories Limited Export?
Caplin Point Laboratories Limited also exports these antifungals products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on Caplin Point Laboratories Limited's Nystatin Exports
The global pharmaceutical export landscape is currently navigating several geopolitical challenges that directly impact companies like Caplin Point.
The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, causing maritime carriers to suspend bookings and reroute vessels around the Cape of Good Hope. This has resulted in elongated lead times and increased shipping costs, disproportionately affecting time-sensitive pharmaceutical shipments. Freight charges have surged, with transport costs doubling and additional surcharges ranging from $4,000 to $8,000 per shipment. Such disruptions pose significant risks to the timely delivery of pharmaceuticals, especially those requiring stringent cold-chain logistics. (pharmaceuticalcommerce.com)
In the United States, recent tariff implementations have introduced further complexities. The U.S. administration has imposed broad tariffs on imports from over 60 countries, including India, with rates reaching up to 39%. These tariffs affect a substantial portion of Indian exports to the U.S., including pharmaceuticals, potentially leading to increased costs and competitive disadvantages for Indian exporters. (apnews.com)
The European Union's regulatory landscape is also evolving, with stricter compliance requirements under directives like the Falsified Medicines Directive. Indian pharmaceutical companies must invest in advanced serialization and traceability systems to meet these standards, ensuring continued access to the lucrative EU market.
For Caplin Point, these geopolitical and regulatory developments necessitate strategic adaptations. Diversifying export markets, enhancing supply chain resilience, and investing in compliance infrastructure are critical to mitigating risks and sustaining growth in this volatile environment.
Caplin Point Laboratories Limited — Regulatory Compliance & Quality Standards
The global pharmaceutical industry is witnessing heightened regulatory scrutiny, particularly from agencies like the U.S. FDA and the European Medicines Agency. Compliance with Good Manufacturing Practices (GMP) and other quality standards is imperative for market access.
Caplin Point has proactively addressed these requirements. The company's subsidiary, Caplin Steriles Limited (CSL), has secured an EU GMP renewal and successfully passed audits by regulatory bodies such as the Saudi FDA. These achievements underscore Caplin Point's commitment to maintaining high-quality standards and ensuring compliance with international regulations. (whalesbook.com)
However, the broader Indian pharmaceutical sector faces challenges related to quality and compliance. The U.S. FDA conducted over 200 inspections in India in 2023, with plans to increase this number in subsequent years. Instances of substandard products have led to increased scrutiny, emphasizing the need for continuous quality improvements. (fact.net.in)
For Caplin Point, ongoing investment in quality assurance systems, employee training, and infrastructure upgrades is essential to navigate the evolving regulatory landscape and maintain its competitive edge.
About Caplin Point Laboratories Limited
Caplin Point Laboratories Limited exports 55 products worth $174.5M. Beyond Nystatin, top products include Ibuprofen, Diclofenac, Clotrimazole, Potassium, Vitamin. View the complete Caplin Point Laboratories Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Nystatin — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Nystatin shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Caplin Point Laboratories Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 66 individual customs records matching Caplin Point Laboratories Limited exporting Nystatin, covering 32 formulations to 7 countries via 12 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 96+ countries, 458+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Nystatin Export Data from Caplin Point Laboratories Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Caplin Point Laboratories Limited's Nystatin exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Caplin Point Laboratories Limited
Full Company Profile →
55 products · $174.5M total trade · 20 categories
Nystatin Stats
Company Overview
Top Products by Caplin Point Laboratories Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Caplin Point Laboratories Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Nystatin. For current shipment-level data, contact TransData Nexus.